About: In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies
Creator	Patel, Ami Weiner, David David, · Weiner, B Bah, Mamadou
Source	PMC
abstract	Antibody immunotherapy is revolutionizing modern medicine. The field has advanced dramatically over the past 40 years, driven in part by major advances in isolation and manufacturing technologies that have brought these important biologics to the forefront of modern medicine. However, the global uptake of monoclonal antibody (mAb) biologics is impeded by biophysical and biochemical liabilities, production limitations, the need for cold-chain storage and transport, as well as high costs of manufacturing and distribution. Some of these hurdles may be overcome through transient in vivo gene delivery platforms, such as non-viral synthetic plasmid DNA and messenger RNA vectors that are engineered to encode optimized mAb genes. These approaches turn the body into a biological factory for antibody production, eliminating many of the steps involved in bioprocesses and providing several other significant advantages, and differ from traditional gene therapy (permanent delivery) approaches. In this review, we focus on nucleic acid delivery of antibody employing synthetic plasmid DNA vector platforms, and RNA delivery, these being important approaches that are advancing simple, rapid, in vivo expression and having an impact in animal models of infectious diseases and cancer, among others.
has issue date	2020-03-10(xsd:dateTime)
bibo:doi	10.1007/s40259-020-00412-3
bibo:pmid	32157600
has license	cc-by
sha1sum (hex)	ce29d6fd830328479838bff6e1e4f5372702abeb
schema:url	https://doi.org/10.1007/s40259-020-00412-3
resource representing a document's title	In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies
has PubMed Central identifier	PMC7211204
has PubMed identifier	32157600
schema:publication	BioDrugs
resource representing a document's body	covid:ce29d6fd830328479838bff6e1e4f5372702abeb#body_text
is schema:about of	named entity 'gene' named entity 'DNA' named entity 'mAb' named entity 'advancing' named entity 'manufacturing' named entity 'global' named entity 'INFECTIOUS DISEASES' named entity 'FIELD' named entity 'INVOLVED' named entity 'MAJOR' named entity 'gene therapy' named entity 'plasmid' named entity 'cancer' named entity 'transport' named entity 'expression' named entity 'cold-chain' named entity 'turn' named entity 'optimized' named entity 'rapid' named entity 'modern medicine' named entity 'biophysical' named entity 'non-viral' named entity 'RNA' named entity 'animal models' named entity 'messenger RNA' named entity 'Nucleic Acid' named entity 'AAV' named entity 'mRNA' named entity 'tropisms' named entity 'antibodies' named entity 'mAb' named entity 'virus' named entity 'antibody' named entity 'antibodies' named entity 'biologics' named entity 'antibody' named entity 'vaccines' named entity 'expression levels' named entity 'antibody' named entity 'mRNA' named entity 'biologics' named entity 'mAbs' named entity 'adverse event' named entity 'mAbs' named entity 'antibody' named entity 'H1N1' named entity 'Zika virus' named entity 'nitrogenous bases' named entity 'DNA transposons' named entity 'route of administration' named entity 'isotypes' named entity 'biosimilars' named entity 'Ebolavirus' named entity 'mAb' named entity 'recombinant' named entity 'complementarity determining regions' named entity 'Plasmid' named entity 'Muthumani' named entity 'clinical trials' named entity 'immune checkpoint inhibitor' named entity 'mice' named entity 'env' named entity 'P. aeruginosa' named entity 'framework region' named entity 'HIV' named entity 'mAb' named entity 'thymidine kinase' named entity 'thymopoiesis' named entity 'CTLA4' named entity 'plasmid DNA' named entity 'animal studies' named entity 'First-line' named entity 'IgG' named entity 'arthritis' named entity 'anti-idiotype' named entity 'viral vector' named entity 'DNA vaccines'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software